Fermentation and cardiovascular risk factors

Completed

• Conditions: Type 2 diabetes/ obesity; type 2 diabetes/ obesity; Nutritional, Metabolic, Endocrine

• Registration Number: ISRCTN35312139
• Lead Sponsor: niversity of Surrey (UK)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2007-08-02
• Last Update Posted: 13 January 2015

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 45

Inclusion Criteria

1. Healthy
2. Fasting insulin >60 pmol/l
2. Male and female 18-60 years

Exclusion Criteria

1. Cardiovascular or endocrine diseases
2. Medication likely to affects either lipid or glucose metabolism

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Insulin sensitivity will be assessed before and after the 12-week intervention by the following: <br>1. Euglycaemic-hyperinsulinaemic clamp <br>2. Liver fat content measured by Magnetic Resonance Imaging [MRI]

Secondary Outcome Measures

Name	Time	Method
The following outcomes are being measured before and after the 12-week intervention: <br>1. Endothelial function, assessed by Pulse Wave Velocity (PWV) and 24-hour blood pressure recordings<br>2. Blood inflammatory markers